Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
Multiple Myeloma
DRUG: chidamide|DRUG: lenalidomide|DRUG: dexamethasone
Response Rate, according to IMWG criteria, including the rate of complete remission (CR), very good partial remission (VGPR) and partial remission (PR), 2 years
Number of participants with treatment-related adverse events, as assessed by CTCAE v4.0, 2 years|Overall Survival Rate, The percentage of people in the study group who are still alive 2 years after the start of treatment, 2 years
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients